{"id":538993,"date":"2021-04-16T19:42:01","date_gmt":"2021-04-16T19:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538993"},"modified":"2021-04-16T19:42:01","modified_gmt":"2021-04-16T19:42:01","slug":"hepatitis-d-virus-infection-market-size-share-trends-competitive-assessment-and-market-forecast-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatitis-d-virus-infection-market-size-share-trends-competitive-assessment-and-market-forecast-report-2030-by-delveinsight_538993.html","title":{"rendered":"Hepatitis D Virus Infection Market Size, Share, Trends, Competitive Assessment and Market Forecast Report 2030 by DelveInsight"},"content":{"rendered":"
\"Hepatitis<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Hepatitis D Virus (HDV) – Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.\n<\/div>\n

DelveInsight<\/strong> launched a new report on Hepatitis D Market Insights, Epidemiology and Market Forecast 2030<\/a>.<\/strong><\/p>\n

DelveInsight’s ‘Hepatitis D Virus (HDV) Market Report 2030’ <\/strong>delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n

Geographies covered are: <\/strong>The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan<\/p>\n

View our detailed report: https:\/\/www.delveinsight.com\/report-store\/hepatitis-d-market<\/a><\/strong><\/p>\n

About the Disease<\/strong><\/p>\n

Hepatitis D is caused by infection with the hepatitis D virus (HDV), also known as Delta Virus, and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV occurs only in individuals positive for the hepatitis B virus (HBV) surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission.<\/p>\n

HDV shares common modes of transmission as HBV and can be acquired either as coinfection or superinfection to HBV. Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to more severe disease in all ages and in 70\u201290% of people.<\/p>\n

Request for our free sample pages: https:\/\/www.delveinsight.com\/sample-request\/hepatitis-d-market<\/a><\/strong><\/p>\n

Hepatitis D Virus Symptoms:<\/strong><\/p>\n

1. Yellowing of the skin and eyes (jaundice)<\/p>\n

2. Gastrointestinal (GI) issues such as nausea, vomiting, and abdominal pain<\/p>\n

3. Tiredness<\/p>\n

4. Loss of appetite<\/p>\n

5. Dark-colored urine<\/p>\n

6. Joint pain<\/p>\n

Hepatitis D Virus Diagnosis<\/strong><\/p>\n

1. Elastography (a special ultrasound that measures the stiffness of the liver)<\/p>\n

2. Liver enzyme function tests<\/p>\n

3. A liver biopsy (wherein a doctor uses a needle to take a small piece of tissue from the liver)<\/p>\n

“In the year 2017, the Total Diagnosed Prevalent cases of HDV was 204,976 in the 7MM which are expected to grow during the study period, i.e., 2017–2030.”<\/strong><\/p>\n

Hepatitis D Virus Emerging Therapy Assessment<\/strong><\/p>\n

1. Hepcludex\/Bulevirtide (MYR Pharmaceuticals\/Hepatera)<\/strong><\/p>\n

2. Lonafarnib (Eiger Biopharmaceuticals)<\/strong><\/p>\n

3. Peginterferon Lambda (Eiger Biopharmaceuticals)<\/strong><\/p>\n

And many others.<\/p>\n

Hepatitis D Virus Market Outlook<\/strong><\/p>\n

Currently, treatment strategies for HDV mainly include interferon (IFN)-based therapy. Antiviral therapy with interferon alfa can be considered in patients with chronic hepatitis D virus (HDV) infection. The treatment course is usually at least 1 year. PegIFNa is the only available drug that has been proven to have some antiviral efficacy against chronic HDV infection. Interferons may be effective at a very early stage of infection when HDV is entering hepatocytes rather than at the stage of established intracellular hepatocyte HDV infection. Recently, Hepcludex has been approved as the first treatment option for adult patients with chronic HDV infection and compensated liver disease in Europe.<\/p>\n

Key Findings:<\/strong><\/p>\n

1. The total market size of HDV<\/strong><\/a> therapies in Japan was USD 23.5 million in 2017 which is expected to increase in the study period (2017–2030).<\/p>\n

2. In 2017, the total market size of HDV therapies was USD 212.4 million in the United States which is expected to increase in the study period (2017–2030).<\/p>\n

3. In 2017, the total market size of HDV therapies was USD 49.2 million in the EU-5 countries which is expected to increase in the study period (2017–2030).<\/p>\n

Download free sample pages of our report: https:\/\/www.delveinsight.com\/sample-request\/hepatitis-d-market<\/a><\/strong><\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Hepatitis D Virus Infection
3 Hepatitis D Virus Infection Market Overview at a Glance
4 Disease Background and Overview: Hepatitis D Virus Infection
5 Case Reports
6 Hepatitis D Virus Infection Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Hepatitis D Virus Infection Treatment and Medical Practices
11 Unmet needs
12 Hepatitis D Virus Infection Marketed Drugs
13 Hepatitis D Virus Infection Emerging Drugs
14 Hepatitis D Virus Infection 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Hepatitis D Virus Infection Market Drivers
19 Hepatitis D Virus Infection Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Hepatitis D Virus (HDV) – Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-538993","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538993"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538993\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}